Trevi Therapeutics (TRVI) Cash from Financing Activities (2018 - 2026)
Trevi Therapeutics (TRVI) posted quarterly Cash from Financing Activities of $222000.0 for Q1 2026, down 97.45% year-over-year from $8.7 million in Q1 2025, and down 21.83% quarter-over-quarter from $284000.0 in Q4 2025.
Trevi Therapeutics (TRVI) Cash from Financing Activities (2018 - 2026) Analysis & Trends
Trevi Therapeutics' Cash from Financing Activities history runs 9 years deep, the most recent figure standing at $222000.0 for Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 97.45% year-over-year to $222000.0; the TTM figure through Mar 2026 stood at $112.5 million (up 60.26% YoY), while the FY2025 annual figure was $121.0 million, up 96.82% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $222000.0, down from $284000.0 in the prior quarter.
- The five-year high for Cash from Financing Activities was $110.4 million in Q2 2025, with the low at -$7.7 million in Q2 2023.
- The 5-year median for Cash from Financing Activities is $1.5 million (2023), against an average of $16.8 million.
- The sharpest annual moves came in 2023 and 2024: Cash from Financing Activities slumped 172.48% in 2023, then jumped 95409.26% in 2024.
- Trevi Therapeutics' Cash from Financing Activities stood at $652000.0 in 2022, then plunged by 108.28% to -$54000.0 in 2023, then surged by 95409.26% to $51.5 million in 2024, then sank by 99.45% to $284000.0 in 2025, then retreated by 21.83% to $222000.0 in 2026.
- Business Quant data shows TRVI's Cash from Financing Activities at $222000.0 in Q1 2026, $284000.0 in Q4 2025, and $1.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Trevi Therapeutics | 2.63 Bn | 2.63 Bn | - | 164.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 164.36 Mn |
| Jun 30, 2026 | 164.36 Mn |
| Mar 31, 2026 | 222,000.00 |
| Mar 31, 2026 | 222,000.00 |
| Dec 31, 2025 | 284,000.00 |
| Dec 31, 2025 | 284,000.00 |
| Sep 30, 2025 | 1.63 Mn |
| Sep 30, 2025 | 1.63 Mn |
| Jun 30, 2025 | 110.40 Mn |
| Jun 30, 2025 | 110.40 Mn |
| Mar 31, 2025 | 8.71 Mn |
| Mar 31, 2025 | 8.71 Mn |
| Dec 31, 2024 | 51.47 Mn |
| Dec 31, 2024 | 51.47 Mn |
| Sep 30, 2024 | 4.98 Mn |
| Sep 30, 2024 | 4.98 Mn |
| Jun 30, 2024 | 5.07 Mn |
| Jun 30, 2024 | 5.07 Mn |
| Mar 31, 2024 | -28,000.00 |
| Mar 31, 2024 | -28,000.00 |